Depletion of R270C Mutant p53 in Osteosarcoma Attenuates Cell Growth but Does Not Prevent Invasion and Metastasis In Vivo

Novel therapeutic targets are needed to better treat osteosarcoma, which is the most common bone malignancy. We previously developed mouse osteosarcoma cells, designated AX (accelerated bone formation) cells from bone marrow stromal cells. AX cells harbor both wild-type and mutant forms of p53 (R270...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Takatsune, Sugihara, Eiji, Takeshima, Hideyuki, Nobusue, Hiroyuki, Yamaguchi, Rui, Yamaguchi-Iwai, Sayaka, Fukuchi, Yumi, Ushijima, Toshikazu, Muto, Akihiro, Saya, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688353/
https://www.ncbi.nlm.nih.gov/pubmed/36429043
http://dx.doi.org/10.3390/cells11223614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688353/
https://www.ncbi.nlm.nih.gov/pubmed/36429043
http://dx.doi.org/10.3390/cells11223614

Ejemplares similares